                               SEQUENCE LISTING

<110> APPLICANT
 
<120> METHODS OF TREATING CHRONIC SPONTANEOUS URTICARIA USING 
      LIGELIZUMAB

<130> PAT058091

<140>
<141>

<160> 8     

<170> PatentIn version 3.5

<210> 1
<211> 107
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      polypeptide

<220>
<223> LIGHT CHAIN VARIABLE REGION OF CLONE CL-2C

<400> 1
Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly 
1               5                   10                  15      


Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Ile Gly Thr Asn 
            20                  25                  30          


Ile His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 
        35                  40                  45              


Tyr Tyr Ala Ser Glu Ser Ile Ser Gly Ile Pro Ala Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser 
65                  70                  75                  80  


Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Ser Trp Ser Trp Pro Thr 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
            100                 105         


<210> 2
<211> 123
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      polypeptide

<220>
<223> HEAVY CHAIN VARIABLE REGION OF CLONE CL-2C

<400> 2
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Met Lys Pro Gly Ser 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Trp Tyr 
            20                  25                  30          


Trp Leu Glu Trp Val Arg Gln Ala Pro Gly His Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Glu Ile Asp Pro Gly Thr Phe Thr Thr Asn Tyr Asn Glu Lys Phe 
    50                  55                  60                  


Lys Ala Arg Val Thr Phe Thr Ala Asp Thr Ser Thr Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Phe Ser His Phe Ser Gly Ser Asn Tyr Asp Tyr Phe Asp Tyr 
            100                 105                 110         


Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 
        115                 120             


<210> 3
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<220>
<223> TES-C21 CDRL1 SEQUENCE (TABLE 1)

<400> 3
Arg Ala Ser Gln Ser Ile Gly Thr Asn Ile His 
1               5                   10      


<210> 4
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<220>
<223> TES-C21 CDRL2 SEQUENCE (TABLE 1)

<400> 4
Tyr Ala Ser Glu Ser Ile Ser 
1               5           


<210> 5
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<220>
<223> CDRL3 VARIANT SEQUENCE #2 (TABLE 1)

<400> 5
Gln Gln Ser Trp Ser Trp Pro Thr Thr 
1               5                   


<210> 6
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<220>
<223> CDRH1 VARIANT SEQUENCE #1 (TABLE 1)

<400> 6
Trp Tyr Trp Leu Glu 
1               5   


<210> 7
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<220>
<223> CDRH2 VARIANT SEQUENCE #2 (TABLE 1)

<400> 7
Glu Ile Asp Pro Gly Thr Phe Thr Thr Asn Tyr Asn Glu Lys Phe Lys 
1               5                   10                  15      


Ala 
    


<210> 8
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<220>
<223> TES-C21 CDRH3 (TABLE 1)

<400> 8
Phe Ser His Phe Ser Gly Ser Asn Tyr Asp Tyr Phe Asp Tyr 
1               5                   10                  


